You are here
Articles on Gastrointestinal Cancer
A selection of peer-reviewed articles on Gastrointestinal Cancer. All content available on the Advances in Gastrointestinal Cancer Resource Center, including original and review articles, interviews, guidelines and congress highlights, is independently selected by the members of the Editorial Board.
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma(FLOT4-AIO)
Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, et al.Lancet Oncol. 2016 Dec;17(12):1697-1708.
Oxaliplatin-Induced Hepatoportal Sclerosis, Portal Hypertension, and Variceal Bleeding Successfully Treated With Transjugular Intrahepatic Portosystemic Shunt
Taoreed O. Lawal, Alton B. Farris, Bassel F. El-Rayes, Ram M. Subramanian, Hyun S. Kim
Clinical Colorectal Cancer
Reversible Posterior Leukoencephalopathy Syndrome During Regorafenib Treatment: A Case Report and Literature Review of Reversible Posterior Leukoencephalopathy Syndrome Associated With Multikinase Inhibitors
Zaw W. Myint, Jeremy M. Sen, Nicole L. Watts, Thomas J. Druzgal, Barnett R. Nathan, Melanie D. Ward, James E. Boyer, Paula M. Fracasso
Clinical Colorectal Cancer, Volume 13, Issue 2, June 2014, Pages 127 - 130
Jane E. Rogers, Aki Ohinata, Arvind Dasari, Cathy Eng
Clinical Colorectal Cancer, Volume 13, Issue 1, March 2014, Pages e1 - e4
Successful Completion of Adjuvant Chemotherapy in a Patient With Colon Cancer Experiencing 5-Fluorouracil–Induced Cardiac Vasospasm
Craig A. Vargo, Marlo Blazer, Joshua Reardon, Martha Gulati, Tanios Bekaii-Saab
Clinical Colorectal Cancer, Volume 15, Issue 2, June 2016, Pages e61 - e63
Posterior Reversible Encephalopathy Syndrome (PRES) After Treatment With Oxaliplatin and 5-Fluorouracil
Nicholas Truman, Daniel Nethercott
Clinical Colorectal Cancer, Volume 12, Issue 1, March 2013, Pages 70 - 72
Grillo F, Fassan M, Sarocchi F, Fiocca R, Mastracci L.World J Gastroenterol 2016 Jul 14;22(26):5879-87.
Chan BA, Jang RW, Wong RK, Swallow CJ, Darling GE, Elimova E.Oncology (Williston Park) 2016 Jul;30(7):635-45. Review.
A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction
Shah MA, Cho JY, Tan IB, Tebbutt NC, Yen CJ, Kang A, et al.Oncologist. 2016 Jul 8. [Epub ahead of print]
Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinoma
Davidson M, Smyth EC, Cunningham D.Onco Targets Ther 2016;9:4539–48.